Ultragenyx Pharmaceutical Inc

For the period ended Jun 30, 2024. Filed Aug 2, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 2, 2024

RARE$16.41+6.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations

(In thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2024	2023	2024	2023
Revenues:
Product sales	$73,805	$42,179	$136,294	$86,408
Royalty revenue	73,221	46,331	119,565	51,213
Collaboration and license	—	19,799	—	71,184
Total revenues	147,026	108,309	255,859	208,805
Operating expenses:
Cost of sales	21,280	9,914	38,813	22,171
Research and development	161,503	164,949	339,990	330,647
Selling, general and administrative	80,604	81,403	158,764	158,049
Total operating expenses	263,387	256,266	537,567	510,867
Loss from operations	(116,361)	(147,957)	(281,708)	(302,062)
Interest income	7,401	5,964	16,225	12,254
Change in fair value of equity investments	(3,991)	261	(245)	(73)
Non-cash interest expense on liabilities for sales of future royalties	(15,960)	(15,375)	(31,807)	(31,011)
Other expense	(1,829)	(1,989)	(3,434)	(1,681)
Loss before income taxes	(130,740)	(159,096)	(300,969)	(322,573)
Provision for income taxes	(858)	(732)	(1,313)	(1,227)
Net loss	$(131,598)	$(159,828)	$(302,282)	$(323,800)
Net loss per share, basic and diluted	$(1.52)	$(2.25)	$(3.54)	$(4.58)
Shares used in computing net loss per share, basic and diluted	86,580,516	70,897,991	85,433,443	70,639,015

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.